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Abstract 
Background: Liver cancer is a common cancer with poor prognosis in China. In this study, the national population‑
based cancer registration data were used to evaluate and analyze liver cancer incidence and mortality in China in 
2011 and provide a reference for liver cancer prevention and control.
Methods: We collected and evaluated the incidence and mortality data of liver cancer in 2011 from 177 cancer 
registries with qualified data. These data were used in the final analysis including calculating crude, standardized, and 
truncated incidences and mortalities, and estimated new liver cancer cases and deaths using age‑specific rates and 
the corresponding populations. The national census in 2000 and Segi’s population were used for age‑standardized 
rates.
Results: The estimates of new liver cancer cases and deaths were 355,595 and 322,416, respectively, in China in 2011. 
The crude incidence, age‑standardized rate of incidence by Chinese standard population (ASRIC), and age‑stand‑
ardized rate of incidence by world standard population (ASRIW) of liver cancer were 26.39/100,000, 19.48/100,000, 
and 19.10/100,000, respectively; the crude mortality, age‑standardized rate of mortality by Chinese standard popula‑
tion (ASRMC), and age‑standardized rate of mortality by world standard population (ASRMW) of liver cancer were 
23.93/100,000,17.48/100,000, and 17.17/100,000, respectively. The incidence and mortality were higher in rural areas 
than in urban areas and higher in males than in females. The age‑specific incidence and mortality of liver cancer 
increased greatly with age, particularly after 30 years and peaked at 80–84 or 85+ years.
Conclusions: Liver cancer is a common cancer in China, particularly for males and residents in rural areas. Targeted 
prevention, early detection, and treatment programs should be carried out.
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Background
Liver cancer is one of the most common malignant 
tumors worldwide. According to GLOBOCAN 2012, it 
was estimated that 782,000 people were diagnosed with 
liver cancer and that 746,000 people died of this dis-
ease, accounting for 5.6% of all new cancer cases and 
9.1% of all cancer deaths worldwide, making liver cancer 
the sixth most common type of cancer and the second 
leading cause of cancer-related death; moreover, more 
than 50% of the incident and death cases occurred in 
China [1]. According to the estimation of the National 
Central Cancer Registry (NCCR) of China, the liver 
cancer incidence and mortality were 27.29/100,000 and 
23.76/100,000, respectively, making it the fourth most 
common cancer and the second leading cause of death in 
2010 [2]. NCCR is responsible for cancer data collection, 
evaluation, and publication in China. In 2014, NCCR col-
lected the incidence and mortality data of liver cancer 
for the calendar year of 2011 from 234 cancer registries. 
Qualified data from 177 registries were accepted to ana-
lyze the incidence and mortality status of liver cancer 
across the country and in different areas to provide a ref-
erence for liver cancer prevention and control.
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Data and methods
Data resources
The incidence and death data of liver cancer in 2011 were 
retrieved from the National Cancer Registry Database 
held by the NCCR of China. The criteria for data quality 
were as follows: the percentage of cases morphologically 
verified (MV%) was higher than 66%, the percentage of 
death certificate-only cases (DCO%) was lower than 15%, 
the mortality to incidence (M/I) ratio was between 0.6 
and 0.8, and the percentage of the diagnosis of unknown 
basis (UB%) was lower than 5%. The registries were strati-
fied into grades A, B, C, and D according to the above cri-
teria for data quality. Among all registries, grades A and 
B registries were included in the annual report, and grade 
C registries, with only individual indices that failed to 
reach the criteria of grade B, were also included as a par-
ticular reason; grade D registries were excluded. The 177 
qualified registries were located in 28 provinces, autono-
mous regions, and municipalities directly under the cen-
tral government: 77 in urban areas and 100 in rural areas. 
The population data came from the Bureaus of Statistics 
or Public Security at cancer registration areas. The 177 
registries covered 175,310,169 people (88,655,668 males 
and 86,654,501 females) and accounted for 13.01% of 
the national population at the end of 2011: 98,341,507 of 
them in urban areas accounted for 56.10% of the popula-
tion covered by the 177 registries, and 76,968,662 in rural 
areas accounted for 43.90%.
National population estimates
The national population in 2011 was estimated based on 
the fifth National Population Census data (2000) pro-
vided by the National Statistics Bureau of China, consid-
ering the changes in the age composition, sex ratio, and 
proportion of urban and rural transformation released 
by the National Bureau of Statistics (http://data.stats.
gov.cn/). The national population in 2011 was stratified 
by area (urban and rural), sex (male and female), and age 
groups (0–, 1–4, 5–84 sub-stratified by 5, and 85+ years). 
The changes in age-specific death probability were also 
adjusted when calculating the national population. Lin-
ear changes were assumed in each age group between the 
fifth and sixth Population Censuses.
Statistical analyses
All liver cancer data coded as C22 in the tenth version 
of the International Classification of Diseases (ICD-10) 
were analyzed. Incident and death cases, proportions, 
and crude, standardized, accumulated, truncated, and 
age-specific incidences and mortalities were calculated 
using the methods recommended by the National Can-
cer Registration Manual [3]. The fifth Chinese National 
Census of 2000 and Segi’s world population were used for 
age-standardized rates. The above indices were calculated 
by region and sex stratifications. Age-specific estimates 
of new cases and deaths at each stratum were obtained 
by multiplying the age-specific incidence and mortality 
with the corresponding populations. The nationwide esti-




The MV%, DCO%, M/I ratio, and UB% of liver cancer 
in 2011 were 37.64%, 4.18%, 0.91, and 0.34% in the 177 
registries, 39.95%, 4.08%, 0.90, and 0.46% in urban areas, 
and 35.10%, 4.29%, 0.92, and 0.22% in rural areas, respec-
tively. Higher data quality was obtained in urban areas 
than in rural areas (Table 1).
Estimated liver cancer incidence
The estimated new liver cancer cases were 355,595, 
accounting for 10.54% of all new cancer cases and mak-
ing liver cancer the third most common cancer in China 
in 2011. The crude incidence, age-standardized rate of 
incidence by Chinese standard population (ASRIC), and 
age-standardized rate of incidence by world standard 
population (ASRIW) of liver cancer were 26.39/100,000, 
19.48/100,000, and 19.10/100,000, respectively. For 
patients aged 0–74  years, the cumulative incidence 
rate was 2.22%; for those aged 35–64  years, the trun-
cated ASRIW (T-ASRIW) was 37.29/100,000. A total of 
264,635 new liver cancer cases were estimated to occur in 
males, accounting for 13.79% of all new cancer cases and 
making liver cancer the third most common cancer in 
Chinese males in 2011. The crude incidence, ASRIC, and 
ASRIW in males were 38.32/100,000, 29.30/100,000, and 
28.65/100,000, respectively. A total of 90,960 new cases 
Table 1 Data quality of  the liver cancer registration 
in China in 2011
M/I mortality to incidence ratio, MV% the percentage of cases morphologically 
verified, DOC% the percentage of death certificate-only cases, UB% the 
percentage of diagnosis of unknown basis
Areas Sex M/I MV% DOC% UB%
All Both sexes 0.91 37.64 4.18 0.34
Males 0.91 37.43 4.08 0.34
Females 0.92 38.24 4.45 0.35
Urban areas Both sexes 0.90 39.95 4.08 0.46
Males 0.89 39.74 3.95 0.43
Females 0.93 40.58 4.44 0.55
Rural areas Both sexes 0.92 35.10 4.29 0.22
Males 0.92 34.86 4.22 0.25
Females 0.91 35.76 4.45 0.13
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were estimated to occur in females, accounting for 6.26% 
of all new cancer cases and making liver cancer the fifth 
most common cancer in Chinese females in 2011. The 
crude incidence, ASRIC, and ASRIW in females were 
13.85/100,000, 9.64/100,000, and 9.55/100,000, respec-
tively (Table  2). Males had a higher liver cancer inci-
dence than females. The numbers of new cases in males 
in urban areas, rural areas, and nationwide were 3.09, 
2.77, and 2.91 times greater, respectively, than those in 
females.
Age‑specific incidence
In 2011, the age-specific incidence of liver cancer 
in China was low before the age of 30  years, rapidly 
increased after the age of 30 years, and peaked at the age 
of 80–84  years (Fig.  1). The age-specific incidence was 
remarkably higher in males than in females. Among dif-
ferent areas, the age-specific incidences varied with a 
similar curve. Notably, after the age of 30 years, the inci-
dence in rural areas was generally higher than that in 
urban areas for both males and females in all age groups, 
except for the age group of 85+ years in males.
Incidence difference between areas
The estimate of new liver cancer cases in urban areas 
in 2011 was 164,528, accounting for 9.11% of all new 
cancer cases and making liver cancer the fourth most 
common cancer in urban areas. The crude incidence, 
ASRIC, and ASRIW in urban areas were 23.82/100,000, 
17.07/100,000, and 16.75/100,000, respectively. The esti-
mate of new liver cancer cases in rural areas in 2011 
was 191,067, accounting for 12.20% of all new cancer 
cases and making liver cancer the fourth most common 
cancer in rural areas. The crude incidence, ASRIC, and 
ASRIW in rural areas were 29.10/100,000, 22.20/100,000, 
and 21.73/100,000, respectively (Table  2). The crude 
incidence, ASRIC, and ASRIW in rural areas were 1.22, 
1.30, and 1.29 times greater than those in urban areas, 
respectively (Table 2).
Estimated liver cancer mortality
Liver cancer deaths were estimated at 322,416, account-
ing for 15.26% of all cancer deaths and making liver 
cancer the second most common cause of cancer death 
in China in 2011. The crude mortality, age-standard-
ized rate of mortality by Chinese standard population 
(ASRMC), and age-standardized rate of mortality by 
world standard population (ASRMW) of liver cancer 
were 23.93/100,000, 17.48/100,000, and 17.17/100,000, 
respectively. For patients aged 0–74  years, the cumula-
tive mortality rate was 1.98%; for those aged 35–64 years, 
the truncated ASRMW (T-ASRMW) was 31.64/100,000. 
An estimate of 239,218 liver cancer deaths occurred in 
males, accounting for 17.77% of all cancer deaths and 
making liver cancer the second most common cause of 
cancer death in Chinese males in 2011. The crude mortal-
ity, ASRMC, and ASRMW in males were 34.64/100,000, 
26.38/100,000, and 25.90/100,000, respectively. An esti-
mate of 83,198 liver cancer deaths occurred in females, 
accounting for 10.85% of all cancer deaths and mak-
ing liver cancer the third most common cause of cancer 
death in Chinese females in 2011. The crude mortality, 
ASRMC, and ASRMW in females were 12.67/100,000, 
8.61/100,000, and 8.51/100,000, respectively (Table  3). 
The mortality was higher in males than in females. The 
numbers of liver cancer deaths in males in urban areas, 
rural areas, and the whole country were 2.96, 2.80, and 
2.87 times greater, respectively, than those in females.
Age‑specific mortality
In 2011, the age-specific mortality of liver cancer in 
China was similar to its age-specific incidence; it was 
Table 2 Liver cancer incidence in China in 2011
Ratio the percentage of liver cancer cases in all new cancer cases, ASRIC age-standardized rate of incidence by Chinese standard population, ASRIW age-standardized 
rate of incidence by Segi’s world standard population, T-ASRIW truncated ASRIW
Areas Sex No. of cases Crude incidence 
(1/105)







All Both sexes 355,595 26.39 10.54 19.48 19.10 2.22 37.29 4
Males 264,635 38.32 13.79 29.30 28.65 3.30 58.22 3
Females 90,960 13.85 6.26 9.64 9.55 1.11 15.62 5
Urban areas Both sexes 164,528 23.82 9.11 17.07 16.75 1.93 32.01 4
Males 124,294 35.25 12.51 26.02 25.51 2.93 50.94 3
Females 40,234 11.90 4.96 8.11 8.00 0.92 12.27 7
Rural areas Both sexes 191,067 29.10 12.20 22.20 21.73 2.53 43.32 4
Males 140,341 41.51 15.17 33.03 32.18 3.71 66.62 3
Females 50,726 15.93 7.91 11.36 11.27 1.33 19.41 5
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low before the age of 30  years, rapidly increased after 
the age of 30 years, and peaked at the age of 80–84 or 
85+ years (Fig. 2). The age-specific mortality was higher 
in males than in females. Among different areas, the 
age-specific mortalities were similar, only with a slight 
difference in the peak age; after the age of 30 years, the 
mortality in rural areas was generally higher than that 
in urban areas for both males and females in all age 
groups, except for the age group of 85+ years.
Mortality difference between areas
Liver cancer deaths in urban areas were estimated at 
146,618, accounting for 13.75% of all cancer deaths 
and making liver cancer the second most common 
cause of cancer death in urban areas in 2011. The crude 
mortality, ASRMC, and ASRMW in urban areas were 
21.22/100,000, 15.04/100,000, and 14.79/100,000, 
respectively. Liver cancer deaths in rural areas were 
estimated at 175,798, accounting for 16.80% of all 
cancer deaths and making liver cancer the second 
most common cause of cancer death in rural areas in 
2011. The crude mortality, ASRMC, and ASRMW in 
rural areas were 26.78/100,000, 20.23/100,000, and 
19.83/100,000, respectively (Table 3). The mortality was 
higher in rural areas than in urban areas. The crude 
mortality, ASRMC, and ASRMW in rural areas were 
1.26, 1.34, and 1.34 times greater than those in urban 
areas, respectively.
Discussion
Liver cancer is a serious problem in developing regions, 
where 83% of new cancer cases worldwide occurred in 
2012. According to GLOBOCAN 2012, the ASRIW and 
ASRMW of liver cancer in 2012 were 10.1/100,000 and 
9.5/100,000 worldwide, 12.0/100,000 and 11.5/100,000 in 
developing countries, and 5.4/100,000 and 4.6/100,000 


























Fig. 1 Age‑specific incidence of liver cancer in China in 2011
Table 3 Liver cancer mortality in China in 2011
Ratio the percentage of liver cancer cases in all cancer deaths, ASRMC age-standardized rate of mortality by Chinese standard population, ASRMW age-standardized 
rate of mortality by Segi’s world standard population, T-ASRMW truncated ASRMW
Areas Sex No. of cases Crude mortality 
(1/105)





Age 35–64  
years
Rank
All Both sexes 322,416 23.93 15.26 17.48 17.17 1.98 31.64 2
Males 239,218 34.64 17.77 26.38 25.90 2.97 49.81 2
Females 83,198 12.67 10.85 8.61 8.51 0.97 12.83 3
Urban areas Both sexes 146,618 21.22 13.75 15.04 14.79 1.68 26.51 2
Males 109,610 31.09 16.33 22.86 22.51 2.57 42.53 2
Females 37,008 10.94 9.36 7.26 7.15 0.80 9.82 4
Rural areas Both sexes 175,798 26.78 16.80 20.23 19.83 2.30 37.50 2
Males 129,608 38.34 19.20 30.37 29.70 3.41 58.24 2
Females 46,190 14.50 12.43 10.13 10.02 1.16 16.22 3
Fig. 2 Age‑specific mortality of liver cancer in China in 2011
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study, there were 355,595 new liver cancer cases and 
322,416 deaths that occurred in 2011, making liver can-
cer the fourth most common cancer and the second lead-
ing cause of cancer-related death in China. The ASRIW 
and ASRMW of liver cancer in China in 2011 were 
19.10/100,000 and 17.17/100,000, respectively; compared 
with the data of GLOBOCAN in 2012, both the incidence 
and mortality of liver cancer in China were at high levels 
worldwide. However, in China, compared with the liver 
cancer data in 2010 [6], the crude incidence, ASRIC, and 
ASRIW in 2011 were lower; the crude mortality in 2011 
was similar to that in 2010, and ASRMC and ASRMW in 
2011 were lower.
In China, in 2011, both the incidence and mortality of 
liver cancer in males were significantly higher than those 
in females. The reasons for the higher rates in males may 
be related to genetic factors [7, 8] and their high propor-
tion of alcohol consumption, which is a risk factor of liver 
cancer [9, 10]. Both the incidence and mortality of liver 
cancer were higher in rural areas than in urban areas. The 
higher incidence in rural areas is most likely related to 
their easy access to risk factors, such as aflatoxin expo-
sure, unhealthy diet habits, polluted water, and blood 
transfusion [11, 12]. Due to the low level of medical treat-
ment and limited medical resources in rural areas, the 
mortality in rural areas was higher than that in urban 
areas. From a population-based cancer survival study, the 
5-year relative survival rate of liver cancer patients was 
10.1% in China, and the survival rate of rural patients was 
less than half of that of their urban counterparts [13]. The 
government should enhance the quality of health ser-
vices, improve the rural medical service level, and bal-
ance medical resources between urban and rural areas 
to bridge the gap. The survival rate of patients with liver 
cancer was generally low in both developed and develop-
ing regions. According to the report from a global sur-
veillance of cancer survival, the 5-year survival rate of 
liver cancer patients is below 20% everywhere in Europe, 
in the range of 15%–19% in North America, and as low as 
7%–9% in Mongolia and Thailand [14]. The prognosis for 
patients with liver cancer is very poor, and advances in 
cancer prevention, early detection, and treatment are the 
main means to reduce the mortality of liver cancer.
With changes in dietary habits and the implementa-
tion of neonatal hepatitis B virus (HBV) vaccination 
for years, infections by aflatoxin and HBV have been 
effectively controlled [15, 16]. The trend analyzed from 
Qidong, Jiangsu showed that the age-standardized rate is 
decreasing, whereas the crude incidence of liver cancer is 
still increasing mainly because of population aging [17]. 
To decrease the incidence and mortality in males and 
in rural areas, targeted prevention, early detection, and 
treatment programs should be carried out, enhancing 
secondary prevention based on strengthening primary 
prevention.
Authors’ contributions
W‑QC and H‑MZ conceived of the study and participated in its design and 
coordination. R‑SZ and S‑WZ performed the statistical analyses and interpreta‑
tion. T‑TZ drafted the manuscript. All authors read and approved the final 
manuscript.
Acknowledgements
We gratefully acknowledged the cooperation of all the population‑based can‑
cer registries in providing cancer statistics, data collection, sorting, verification, 
and database creation.
Competing interests
The authors declare that they have no competing interests.
Received: 25 June 2015   Accepted: 7 September 2015
References
 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. 
Cancer incidence and mortality worldwide: sources, methods and major 
patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
 2. Chen WQ, Zheng RS, Zhang SW, Zhao P, Zeng HM, Zou XN, et al. 
Annual report on status of cancer in China, 2010. Chin J Cancer Res. 
2014;26:48–58.
 3. National Office for Cancer Control and Prevention, Information Centre of 
Health Statistics of Health Ministry, National Centre for Cancer Registra‑
tion. Guideline for cancer registration in China. Beijing: Military Medical 
Science Press; 2004. p. 50–7 (in Chinese).
 4. Chen WQ, Zheng RS, Zeng HM, Zhang SW, He J. Annual report on status 
of cancer in China, 2011. Chin J Cancer Res. 2015;27:2–12.
 5. International Agency for Research on Cancer. GLOBOCAN 2012: esti‑
mated cancer incidence, mortality and prevalence worldwide in 2012. 
2014. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 23 
Apr 2015.
 6. Wei KR, Yu X, Zheng RS, Peng XB, Zhang SW, Ji MF, et al. Inci‑
dence and mortality of liver cancer in China, 2010. Chin J Cancer. 
2014;33:388–94.
 7. Sander LE, Trautwein C, Liedtke C. Is interleukin‑6 a gender‑specific risk 
factor for liver cancer? Hepatology. 2007;46:1304–5.
 8. Su CH, Lin Y, Cai L. Genetic factors, viral infection, other factors and 
liver cancer: an update on current progress. Asian Pac J Cancer Prev. 
2013;14:4953–60.
 9. Fan JH, Wang JB, Jiang Y, Xiang W, Liang H, Wei WQ, et al. Attributable 
causes of liver cancer mortality and incidence in China. Asian Pac J Can‑
cer Prev. 2013;14:7251–6.
 10. Lee EY, Xuan Mai TT, Chang Y, Ki M. Trends of liver cancer and its major risk 
factors in Korea. Epidemiol Health. 2015;37:e2015016.
 11. Fukuda A, Sugimachi K, Tokudome S, Ikeda M, Koga S, Hirohata T. Blood 
transfusion as a risk factor for cirrhosis and liver cancer: a matched case‑
control study. J Natl Cancer Inst. 1989;81:1189–90.
 12. Yang BH, Zhang BH. Risk factors and prevention for primary liver cancer. 
Linchuang Gan Dan Bing Za Zhi. 2012;28:253–5 (in Chinese).
 13. Zeng HM, Zheng RS, Guo YM, Zhang SW, Zou XN, Wang N, et al. Cancer 
survival in China, 2003–2005: a population‑based study. Int J Cancer. 
2015;136:1921–30.
 14. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. 
Global surveillance of cancer survival 1995–2009: analysis of individual 
data for 25,676,887 patients from 279 population‑based registries in 67 
countries (CONCORD‑2). Lancet. 2015;385:977–1010.
 15. Qu CF, Chen TY, Fan CS, Zhan QM, Wang YT, Lu JH, et al. Efficacy of 
neonatal HBV vaccination on liver cancer and other liver diseases over 
30‑year follow‑up of the Qidong hepatitis B intervention study: a cluster 
randomized controlled trial. PLoS Med. 2014;11:e1001774.
Page 6 of 6Zuo et al. Chin J Cancer  (2015) 34:56 
 16. Chen JG, Egner PA, Ng D, Jacobson LP, Munoz A, Zhu YR, et al. Reduced 
aflatoxin exposure presages decline in liver cancer mortality in an 
endemic region of China. Cancer Prev Res. 2013;6:1038–45.
 17. Chen JG, Zhu J, Zhang YH, Chen YS, Ding LL. Incidence trend of liver can‑
cer: an analysis of 40 years data from Qidong population‑based cancer 
registry. Zhongguo Zhong Liu. 2014;23:621–8 (in Chinese).
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
